Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
PR Newswire - Mon Sep 15, 8:30AM CDT
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States.
Attunity, Ltd. (ATTU) in Focus: Stock Adds 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 8:18AM CDT
Attunity, Ltd. was a big mover last session, as the company saw its shares rise more than 5% on the day.
Global Cardiac POC Market 2014-2018: Key Vendors are Alere, Abbott Laboratories and Roche Diagnostics
PR Newswire Europe - Mon Sep 15, 7:12AM CDT
DUBLIN, Sept. 15, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] has announced the addition of the "Global Cardiac POC Market 2014-2018" [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] report to their offering.
ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent
PR Newswire Europe - Sun Sep 14, 10:00AM CDT
-- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:50PM CDT
In an effort to increase shareholder value, Abbott Laboratories' (ABT) board of directors has approved a new share repurchase program.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
The Zacks Analyst Blog Highlights: Mylan, Abbott Laboratories, Mallinckrodt, Gilead Sciences and Baxter International
PR Newswire - Fri Sep 12, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Mylan Inc. (Nasdaq:MYL-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Mallinckrodt (NYSE:MNK-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report) and Baxter International Inc. (NYSE:BAX-Free Report).
Latin America Home Healthcare (Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies) Market 2014-2020
M2 - Fri Sep 12, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63pfn7/latin_america) has announced the addition of the "Latin America Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The Latin America home healthcare market is estimated to be USD 9,796.8 million in 2013 and is expected to reach USD 17,550.0 million by 2020, growing at a CAGR of 8.7% from 2014 to 2020 Home healthcare represents use of medical devices and community based services to support patients suffering from chronic diseases. Currently, the home healthcare market is moving towards a precision-based model of personal care. Home-based medical devices and services play an important role in providing personal care to patients in managing variety of disease conditions such as diabetes, chronic obstructive pulmonary disease and blood pressure. Increasing patient population with chronic diseases such as diabetes, blood pressure, cardiovascular conditions and respiratory diseases globally (including Latin America) would drive the demand for home-based medical devices and services. These diseases require continuous monitoring, and thus involve high cost due to repeated visits to healthcare centers that inflate medical expenses. Thus, home healthcare devices and services are being rapidly adopted by consumers to measure parameters on a regular basis and to cut down medical costs. Latin America home healthcare market is mainly segmented into device types and services. Latin America home healthcare device segment is considered to be the largest segment and is estimated to grow at the highest CAGR during the forecast period from 2014 to 2020. This growth was mainly attributed to high acceptance of medical devices coupled with technological advancements (introduction of automated and portable devices) to fuel the growth of the home healthcare devices market in Latin America. The market of ventilators and CPAP devices segment is estimated to grow at the highest CAGR of 11.4% from 2014 to 2020. The mobility assist devices segment is further categorized into wheelchairs, cranes and crutches and other home mobility assist devices. Latin America home healthcare market, by services is segmented as rehabilitation services, intuition therapy services, telehealth and telemedicine services, respiratory therapy services and unskilled home healthcare services. The Latin American market of unskilled home healthcare services accounted for the largest market share i.e. more than 45% of total Latin American home healthcare services market in 2013. The telehealth and telemedicine services segment is estimated to grow at the highest growth rate from 2014 to 2020. The Latin American home healthcare market is segmented as follows: Latin American Home Healthcare Market, by Device Types - Diagnostics and Monitoring Home Devices - - Blood Glucose Monitors - - Blood Pressure Monitors - - Heart Rate Monitors - - Temperature Monitors - - Sleep Apnea Monitors - - Coagulation Monitors - - Pregnancy Test Kits - - Pulse Oximeters - - Pedometers - Therapeutics Home Healthcare Devices - - Insulin Delivery Devices - - Nebulizers - - Ventilator and CPAP Devices - - IV Equipments - - Dialysis Equipment - Home Mobility Assist Devices - - Wheelchairs - - Cranes and Crutches - - Other Home Mobility Assist Devices - Medical Supplies Latin American Home Healthcare Market, by Services - Rehabilitation Services - Telehealth and Telemedicine Services - Infusion Therapy Services - Respiratory Therapy Services - Unskilled Home Healthcare Services Companies Mentioned - 3M Healthcare - Abbott Laboratories - Bayer AG - Cardinal Health - F. Hoffmann-La Roche Ltd. - GE Healthcare - Gentiva Health Services, Inc. - Invacare Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Omron Healthcare, Inc. - Philips Healthcare - Praxair Technologies, Inc. - ResMed, Inc. - Teleflex Incorporated - The Linde Group For more information visit http://www.researchandmarkets.com/research/63...in_america
Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Sep 11, 5:45PM CDT
Eli Lilly (LLY) and Boehringer Ingelheim's product is the first biosimilar insulin to receive regulatory approval in the EU.
Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
Abbott Laboratories (ABT) Declares Quarterly Dividend, Announces Share Buyback
at The Street - Thu Sep 11, 1:29PM CDT
Abbott Laboratories (ABT) declared its quarterly dividend of 22 cents a share Thursday, in line with its previous dividend.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
PR Newswire - Thu Sep 11, 12:39PM CDT
Abbott's (NYSE: ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend.
Abbott Laboratories (ABT) Crosses Pivot Point Support at $42.67
Comtex SmarTrend(R) - Thu Sep 11, 10:36AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.86 and have already reached the first level of support at $42.67. Analysts will be watching for a cross of the next downside pivot targets of $42.44 and $42.02.
Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
PR Newswire Europe - Thu Sep 11, 9:59AM CDT
- Abbott Achieved Top Industry Scores for Economic and Social Performance